Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life ExperienceArticle Published on 2021-07-292022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] adopted Area average baseline Biologic therapy clinical trial collected condition conducted Course COVID-19 defined disease drug Effect exclusion criteria experience female immunized immunomodulating Impact index life male management Mild New coronavirus not differ Patient Prophylactic psoriasis reduction Research Safety safety profile severe adverse event severity significantly subject therapy Treatment treatment with biologics vaccination Vaccine [DOI] 10.3390/jcm10153355 PMC 바로가기 [Article Type] Article
Evaluation of the safety profile of COVID-19 vaccines: a rapid reviewResearch Article Published on 2021-07-282022-10-28 Journal: BMC Medicine [Category] COVID-19, SARS, [키워드] accounted adverse event age article candidate vaccine Candidates clinical trial clinical trials COVID-19 COVID-19 vaccine COVID-19 vaccines DNA vaccine eligible Evidence fatigue follow-up time Frequency group headache heterogeneity Human Inactivated vaccine incidence indicate Injection-site pain lack Local Meta-analysis Novel coronavirus diseases 2019 observational study outcome platform PMC pooled rate proportion protein subunit vaccine rapid process Reactions recipient Regulatory Reporting Research Result review RNA vaccine safety profile searched Serious Adverse Event severe acute respiratory syndrome coronavirus 2 significantly lower supplementary material Surveillance surveillance data systemic reaction systemic reactions treatment groups Vaccine virus-like particle vaccine was performed Web of Science [DOI] 10.1186/s12916-021-02059-5 PMC 바로가기 [Article Type] Research Article
Abbreviated Profile of Drugs (APOD): modeling drug safety profiles to prioritize investigational COVID-19 treatmentsResearch article Published on 2021-07-282022-10-05 Journal: Heliyon [Category] 신약개발, 치료법, 치료제, [키워드] Abbreviated Profile of Drugs (APOD) ADMET administer Analysis APOD approved approved drug Cancer category clinical development clinical trial coronavirus disease COVID-19 COVID-19 treatment criteria database dataset demonstrated Dexamethasone drug Drug discovery Drug safety profile effective EIDD-2801 examined facilitated FDA food GDC-0941 imperative inhibitors methodology moderate molnupiravir organ-specific P450 Pharmacokinetic prediction profile progression recalled resources safety profile tested toxicities transmitted Transport withdrawn [DOI] 10.1016/j.heliyon.2021.e07666 [Article Type] Research article
Just a Reflection: Does Drug Repurposing Perpetuate Sex-Gender Bias in the Safety Profile?Review Published on 2021-07-272022-10-28 Journal: Pharmaceuticals [Category] COVID-19, [키워드] appear approach approved drug Bia Clinical tests COVID-19 dosage downregulation drug enzyme evaluated Gender immune system increase infective Inflammation inflammatory disease lack men Modification MOST occur parameters Patient performed pharmacokinetic pharmacokinetics Phase I profiles reduce regimen repurposing Safety safety profile severe COVID-19 Sex Treatment turn women [DOI] 10.3390/ph14080730 PMC 바로가기 [Article Type] Review
Sex Disparities in Efficacy in COVID-19 Vaccines: A Systematic Review and Meta-AnalysisArticle Published on 2021-07-272022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] 95% CI adaptive Analysis article available data clinical trial Clinical trial design conducted control group COVID-19 COVID-19 cases COVID-19 vaccine COVID-19 vaccines database described disparity Efficacy Efficacy and safety eligible Evidence Gender heterogeneity immune system include innate immune response investigated men Meta-analysis occur profile review Safety safety profile SARS-CoV-2 Sex Sex difference shown significantly higher stratified by sex systematic review the vaccine Toxicity Vaccine Vaccines was performed women [DOI] 10.3390/vaccines9080825 PMC 바로가기 [Article Type] Article
Design and proof of concept for targeted phage-based COVID-19 vaccination strategies with a streamlined cold-free supply chain423 Published on 2021-07-272022-10-29 Journal: Proceedings of the National Academy of Sciences of [Category] COVID-19, [키워드] AAVP Administered aerosolization Antibody Response Antigen approach attributes Bacteria circulation CMV promoter coronavirus disease COVID-19 COVID-19 pandemic COVID-19 vaccination COVID-19 vaccine COVID-19 vaccine development development displaying effective vaccine elicit Emergency use authorization epitope experiments expression gene delivery Genetic highly pathogenic humans humoral immune response immunization imperative infect inherent initial injected Ligand lung lung epithelium mice Particle Particles peptide performed phage phage display plasticity platform Protein Rapid Research robust S protein S protein-specific antibody safety profile SARS-CoV-2 SARS-CoV-2 S protein Significance stability subcutaneous vaccination sustained temperature the SARS-CoV-2 transgene translational Transport unique vaccination Vaccine Vaccine development virus widespread [DOI] 10.1073/pnas.2105739118 PMC 바로가기 [Article Type] 423
Development and Delivery Systems of mRNA VaccinesBioengineering and Biotechnology Published on 2021-07-272022-10-31 Journal: Frontiers in Bioengineering and Biotechnology [Category] COVID-19, [키워드] administration allergy Analysis Antigen approach biosafety carrier cells clinical trial COVID-19 mRNA vaccine Cytokine storms Degradation delivery development DNA vaccines drug delivery ENhance expressed heart failure highlighting immune responses Infarction inherent limitations molecular molecular design mRNA mRNA vaccine mRNA vaccines outbreak renal Research risk safety profile SARS-CoV-2 Side effect System the vaccine Vaccines while [DOI] 10.3389/fbioe.2021.718753 PMC 바로가기 [Article Type] Bioengineering and Biotechnology
Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial건강한 성인의 코로나바이러스 질병 2019에 대한 재조합 융합 단백질 백신(V-01)의 면역원성과 안전성: 무작위 배정, 이중 맹검, 위약 대조, 2상 시험Clinical Trial Published on 2021-07-222022-09-12 Journal: Chinese medical journal [Category] SARS, 임상, 진단, [키워드] acute respiratory syndrome Adults adverse event AEs age anti-RBD Antigen appear China clinical trial clinical trials confidence interval Control convalescent serum coronavirus coronavirus disease COVID-19 COVID-19 patient demonstrated distribution dose regimen dosing regimens double-blind Efficacy elevated Endpoint Frequency fusion protein geometric mean titer group Guangdong healthy IFN-PADRE-RBD-Fc dimer immune response immune responses immunization immunogenic immunogenicity Immunoglobulin imperative indicated initiated injection intramuscularly less mild in severity neutralizing antibody Older pandemic participant peaked percentage Phase I Placebo placebo-controlled Preliminary data preliminary finding prevention primary immunogenicity Randomized RBD reactogenicity receive Receptor binding domain recombinant COVID-19 vaccine recombinant fusion protein recruited regimen remained robust Safe safety profile significantly specific binding antibody Support symptomatic Trial two-dose regimen V-01 Vaccine vaccine candidate Vaccines [DOI] 10.1097/CM9.0000000000001702 PMC 바로가기 [Article Type] Clinical Trial
Drug-Induced Liver Injury After COVID-19 VaccineGastroenterology Published on 2021-07-192022-10-31 Journal: Cureus [Category] COVID-19, [키워드] administration approved caused China coronavirus disease COVID-19 COVID-19 infection COVID-19 pandemic COVID-19 vaccine drug drug-induced Drug-induced liver injury Emergency use globe liver dysfunctions Liver injury morbidity and mortality pandemic patients who survived persistent reported safety profile serious complication Side effects Symptom the vaccine Vaccine World Health Organization [DOI] 10.7759/cureus.16491 PMC 바로가기 [Article Type] Gastroenterology
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey비활성화된 전체 비리온 SARS-CoV-2 백신(CoronaVac)의 효능 및 안전성: 터키에서 이중 맹검, 무작위, 위약 대조, 3상 시험의 중간 결과Clinical Trial Published on 2021-07-172022-09-12 Journal: Lancet (London, England) [Category] Fulltext, SARS, 임상, 진단, [키워드] 1:1 95% CI adverse event adverse events antibody test result bleeding disorders blood product clinical trial Cohort component CoronaVac COVID-19 criteria dose double-blind Efficacy Efficacy and safety enrolled exclusion fatality fatigue follow-up period Frequency health-care humoral hydroxide Immunoglobulin immunosuppressive inactivated individual intention-to-treat intention-to-treat population intramuscularly IQR Local median Negative PCR nine Older outcome Pain participant PCR-confirmed per 1000 person-years per protocol Phase 3 phase 3 trial Placebo placebo-controlled protocol provided randomised Randomly recruited Registered reported safety analysis safety profile SARS-CoV-2 screened second dose shown Steroids symptomatic the placebo group the vaccine therapy Tolerability trials Turkey Vaccine virion virus Volunteer whole-virion SARS-CoV-2 vaccine yielding [DOI] 10.1016/S0140-6736(21)01429-X PMC 바로가기 [Article Type] Clinical Trial